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Abstract
The dried fruits of the chaste tree Vitex agnus castus (VAC) were traditionally used by monks as a substitute for
pepper and was therefore also called Monk’s pepper. For the last 50 years it is commercially provided for the
treatment of premenstrual symptoms, particularly to prevent premenstrual mastodynia (mastalgia). Most studies
were performed with the preparation containing an aqueous/ethanolic ectract BNO 1095. A number of placebo
controlled studies gave proof that extracts of VAC had beneficial effects on premenstrual breast pain. This breast
sensation is induced by latent hyperprolactinemia which is characterized by secretory episodes of prolactin release
by the pituitary in response to stress and deep sleep phases. This latent hyperprolactinemia induces also often a
corpus luteum insufficiency which is a common reason for infertilty.
It is well accepted that prolactin release can be reduced by dopamine and dopaminergic drugs. The efficacy of VAC
extracts to ameliorate prolactin induced premenstrual mastodynia was therefore suggestive that VAC may contain
dopaminergic compounds. Indeed, a number of diterpenes were identified that bound to recombinant Dopamine
receptors of the 2 subtype (D2 receptors) which are present in pituitary lactotropes and which mediate the
inhibitory effects of dopamine and dopaminergic drugs on pituitary prolactin release. Consequently, prolactin
release in vitro from dispersed pituitary cells and in vivo in rats and postmenopausal women was inhibited by VAC
1095. Placebo controlled studies proved also the efficacy of VAC extracts to ameliorate premenstrual symptoms. In
several placebo-controlled studies a clear relation between reduction of breast pain and reduction of serum prolac-
tin levels could be established. In addition VAC extracts was also highly effective in women suffering from fibro-
cystic mastopathy. In many of these women serum prolactin levels were also elevated and reduced by VAC
extracts.
The results from all trials suggested that VAC extracts ameliorated premenstrual symptoms including mastodynia,
premenstrual dysphoric disorder and latent hyperprolactinemia. Cystic mastopathy and sterility due to corpus
luteum insufficiencies were also beneficially influenced.
Adverse events with VAC were mild and generally infrequent.
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Introduction
The Premenstrual Syndrome (PMS) also called premen-
strual disorders (PMDs) affect up to 70% of women and
between 10–20% of them have a severe form, the Pre-
menstrual Dysphoric disorder (PMDD). The definition,
diagnosis and management have always been challen-
ging. These conditions affect reproductive aged women
and can have a substantial impact on quality of life, with
resultant impairment of education/work. The definition
of PMSD is somehow weak but there is consensus that
symptoms of the core menstrual disorders occur pemen-
strually, may occur already during the luteal phase but
exacerbate premenstrually and ease during the men-
strual period. The symptoms may be primarily psychic
or somatic with a wide overlap. The most common
symptoms of PMS are listed in Table 1.
Premenstrual syndrome (PMS), mastodynia,
prolactin and infertility
One of the most common and frightening symptoms for
women is premenstrual breast pain - premenstrual mas-
todynia - which occurs in more than 20% of the female
population. When this discomfort is extreme it is classi-
fied as mastalgia (severe mastodynia) [1–3]. There is evi-
dence that in women suffering from premenstrual
mastodynia or mastalgia a latent hyperprolactinemia is
one of the major reasons for the development of the
complaints [3, 4]. Patients suffering from premenstrual
mastodynia have under resting conditions often normal
serum prolactin levels, under stress situations however,
pituitary prolactin release seems to be augmented. The
spontaneous release of prolactin occurs in pulses and in
the luteal phase these pulses occur synchronously with
LH pulses [5]. In women with a latent hyperprolactine-
mia these prolactin pulses are higher than in women
with normal prolactin release (Fig. 1). Hence, highest
prolactin pulses in women suffering from PMS are ob-
served in the late luteal and the premenstrual phase
(Fig. 1) and also stress and deep sleep induced prolactin
release is exaggerated during the luteal phase. This was
studied in some more detail and results are shown in
Fig. 2. These results stem from a study comprising
women with PMdy and women without breast discom-
fort. They were investigated during the late luteal phase.
Prolactin levels in women suffering of premenstrual
mastodyniay were in a pathologic range i.e. > 500 μU.
Such effects were not observed in the women who did
not suffer from premenstrual breast pain. Interesting, in
comparison to women without breast complaints the
women with premenstrual mastodynia had significantly
lower serum progesterone values and these low levels
were in the pathologic range indicating a corpus luteum
insufficiency (Fig. 2) which is a common reason for in-
fertility. These findings confirm and extend earlier re-
sults demonstrating increased prolactin and low
progesterone levels in women suffering from premen-
strual mastodynia [3, 6, 7].
It is currently generally accepted that high and fre-
quently occurring prolactin episodes stimulate prolifera-
tion of mammary gland tissue causing the uncomfortable
breast sensations, i.e. mastodynia (mastalgia) [8]. Hence,
the latent hyperprolactinemia mimicks effects seen during
early pregnancy [9].
Taken together it appears quite clear that latent hyper-
prolactinemia is a, if not the major cause of premen-
strual mastodynia, mastalgia and infertility due to
insufficient function of the corpus luteum. It was there-
fore very early attempted to cure the painful breast sen-
sations by drugs which inhibit pituitary prolactin release.
Under physiologic conditions the biogenic amine dopa-
mine inhibits pituitary prolactin release. This has led to
development of synthetic drugs with dopaminergic activ-
ity which were all derivatives of ergot alkaloids. It be-
came soon clear that decreased prolactin levels under
treatment with the dopamine receptor agonist bromo-
criptine ameliorated the severity of premenstrual masto-
dynia, an effect not seen in the placebo treated patients
[3, 10]. Also, a study addressing the question whether
the synthetic dopamine agonist lisuride ameliorates also
other PMS symptoms yielded positive results [11]. But
these systemic dopaminergic drugs had all severe side
effects such as nausea and orthostatic dysregulation [12].
Treatment options with Vitex agnus castus (VAC)
As mentioned above synthetic dopaminergic drugs ame-
liorated premenstrual symptoms including mastodynia.
Due to severe side effects of these drugs many women
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PMDY n=31
No PMDY n=42
Fig. 2 Infertile patients with premenstrual mastodynia (PMDY) have often a moderate hyperprolacinemia (i.e. values > 500 μU/ml) during the
midluteal phase and this is associated with low serum progesterone. Women who do not suffer under PMDY have normal prolactin and













































































































































Fig. 1 In women who do not suffer from premenstrual mastodynia LH pulses during the luteal phase occur relatively regular at 2–4 h intervals.
These pulses are accompanied by prolactin pulses and are stimulatory to progesterone secretion by the corpus luteum (upper graph). In
women suffering from premenstrual mastodynia the prolactin pulses are often of such a height that-at their peak time-one could suspect
a pituitary prolactinoma. In the woman show in the lower graph LH pulses are of normal height gut the corpus luteum fails to respond
with increade progesterone secretion
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do refuse to use conventional treatment with hormones
or psychopharmaceuticals and seek often for plant de-
rived alternatives which become therefore increasingly
prevalent in the Western world. In this context, the ex-
tracts of Vitex agnus-castus fruit (VAC, chaste tree, chas-
teberry; family: Verbenaceae) are commonly used for the
treatment of premenstrual syndrome which-as elabo-
rated above-is often associated by premenstrual masto-
dynia, premenstrual dysphoric disorder (PMDD) and
corpus luteum insufficiency.
Pharmacology of VAC
A number of plants produce substances which bind to
one or both estrogen receptors (ERα and ERβ). Most ad-
verse effects of estrogens in the mammary gland and
uterus are exerted via the ERα. The uterotrophic assay
in ovariectomized rats is the OECD recommended test
system for ERα activity [13]. Administration of the VAC
extract BNO 1095 over a period of 3 months even at
high doses neither stimulated uterine weights nor were
estrogen stimulated genes affected (Fig. 3a, b and c, un-
published data). In earlier studies we demonstarted the
presence of apigenin in VAC BNO 1095 which binds to
ERß [14]. In another study [15] linoleic acid was isolated
from a VAC extract which stimulated some ERα specific
events in ERα expressing cells and recently some
substances have been isolated with affinities to both ER
subtypes [16].
Particularly the beneficial effects of VAC extract on
mastalgia were suggestive that extracts of the dried fruit
may contain dopaminergic compounds which inhibit pi-
tuitary prolactin release. Consequently it was indeed
shown that VAC extracts may fulfill these prolactin inhi-
biting conditions [17–19]. Dopaminergic activity via
binding to dopamine-2 (DA-2) receptors [17] was
proven by several experimental approaches:
1. Radioreceptorassays
The D2 receptor is nowadays available as
recombinant protein. When incubated with
radioactively labeled dopamine a large fraction of
this labeled amine binds to the receptor and this
bound radioactive dopamine can be dose
dependently displaced by non labeled dopamine
(Fig. 4). When the VAC extract BNO 1095 was
added instead of the non labeled dopamine this
resulted also in a dose dependent displacement of
the labeled dopamine (Fig. 4) indicating binding to
the recombinant dopamine receptor and thereby
displacing the radioactively labeled dopamine from
the receptor.
2. In vitro studies
Rat pituitary cells, kept under culture conditions
secrete large amounts of prolactin and this can be
effectively inhibited by dopamine and dose
dependently by the VAC extract BNO 1095 which is
used commercially for the production of
Mastodynon and Agnucaston (Fig. 5). The receptor
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Fig. 3 Treatment of ovariectomized rats with estradiol 17ß stimulates
uterine weight (a), progesterone receptor gene expression (b) and the
expression of the IGF 1 gene (c). Such effects are not seen in the VAC
treated animals
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haloperidol, a specific dopamine receptor antagonist
prevented the inhibitory effects of dopamine as well
as of the VAC extract (Fig. 5).
3. In vivo studies
a. In rats
It was already mentioned above that stress is a
potent stimulus for pituitary prolactin release in
women. Also rats react to stress with massive
release of prolactin (Fig. 6). When rats were
pretreated with the VAC extract BNO 1095 prior
to application of an ether stress this prevented
prolactin release significantly (Fig. 6).
b. In women
Also women suffering from premenstrual
mastodynia have supraphysiologic high prolactin
pulses resulting premenstrually in
supraphysiologic mean prolactin levels (Fig. 1 and
2). Such high prolactin levels can be normalized
by the treatment with the BNO 1095 containing
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Fig. 4 Radioactively labeled dopamine (DA) binds to recombinant DA receptors and increasing amounts of non labeled DA displaces the
radioactively labeled DA. After separation of bound from non bound DA this results in a standard curve. Any substance which also displaces the
radioactively labeled DA indicates that it binds also to the DA receptor. The VAC extract BNO 1095 displaces the radioactively labeled DA from
the DA receptor which is evidence for the presence of dopaminergic compounds
Fig. 5 Dispersed rat pituitary cells secrete large amounts of prolactin which are profoundly inhibited by DA. The VAC extract BNO 1095 inhibits
prolactin release which is further evidence for dopaminergic activity of this extract. The DA 2 receptor specificity is proven by the reduction of
the inhibitory effects of both, DA and VAC BNO 1095 by haloperidol, a DA 2 receptor blocker
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[19]. In this and in another trial [20] the effects of
a VAC BNO 1095 containing preparation on
premenstrual mastodynia were significantly better
than those of placebo (Fig. 7).
In attempts to identify the dopaminergic substances 2
different VAC extracts (one of them was BNO 1095)
were shown to contain a number of diterpenes with
dopaminergic activities [18, 19]. In addition to these
prolactin inhibiting substances VAC extracts were shown
to contain flavonoids which bound to μ- and δ-opioid
receptors and it was suggested that such compound may
also ease premenstrual symptoms [21].
Clinical studies
Most publications specified several different VAC prepa-
rations with VAC BNO 1095 present in Mastodynon®
and Agnucaston®. The PMS studies as well as studies on
mastodynia/mastalgia, latent hyperprolactinemia and
fibrocystiv mastopathy are specified in Table 2. The most
commonly prescribed dose was 40 mg/day dried fruit
which is equivalent to 4.0 mg extract.
Fourteen of 21 PMS studies were placebo-controlled
while 7 studies compared the effects of VAC with the
serotonin reuptake inhibiting antidepressant fluoxet-
ine, or with other plant derived non-estrogenic
extracts or with pyridoxine (vitamin B6) and magne-
sium, respectively.
PMS
According to our literature survey 21 studies were pub-
lished in which effects of VAC extracts on PMS were in-
vestigated (Table 2 a-c). In all but one study beneficial
effects on all symptoms listed in Table 1 were reported.
Mastodynia and fertility
As outlined above stress- and sleep related increased
prolactin levels appear to inhibit corpus luteum function
and to reduce the secretion of progesterone in the luteal
Fig. 6 In female rats the response to a stressful stimulus (in this case ether stress) results in marked prolactin release. Application of the VAC
extract BNO 1095 ameliorated this stress induced prolactin release significantly giving further evidence to the presence of dopaminergic
compounds in this extract
Fig. 7 In 2 trials the effects of Mastodynon/Agnucaston on
premenstrual Mdy were significantly superior to those of Placebo
(upper part) (Wuttke et al. 2003, Halaska et al. 2003)
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phase of the menstrual cycle [22] and this has led to
clinical studies in latent hyperprolactinemic women with
premenstrual mastodynia (Fig. 2). Improved fertility was
later confirmed in a trial involving 44 infertile patients
due to luteal phase defects, treatment with 40 mg of a
dried Vitex agnus castus (VAC BNO 1095) preparation
increased both, serum progesterone and estradiol [23,
24]. Following this treatment ovulatory cycles were
present in 93% and fertility rate was restored in 71.4% of
the patients. These results are comparable to those
shown in Figs. 1 and 2 and indicate that VAC extracts
may indeed be helpful in cases of infertility. The same
group demonstrated a significant reduction of serum
prolactin levels under a VAC preparation in patients suf-
fering from polycystic ovarian disease [24].
How can the effects of VAC on luteal function be ex-
plained? Continuously high prolactin levels inhibit the
hypothalamic pulse generator [25]. This results in infer-
tility because normal gonadotropin release is inhibited.
In latent hyperprolactinemic patients the hypothalamic
GnRH pulse generator appears to function normally be-
cause LH pulses of normal height are present (Fig. 1).
Hence we face the possibility that the exaggerated height
of prolactin pulses during the luteal phase (Fig. 1) have a
direct inhibitory effect on luteal progesterone secretion.
It appears therefore safe to conclude that VAC prepara-
tions contain dopaminergic substances which normalize
the exaggerated height of prolactin pulse which allows
normal luteal progesterone secretion, thereby preventing
luteal insufficiency and promoting fertility. This sugges-
tion is graphically outlined in Fig. 8.
Another additional positive effect of the dopamin-
ergic effects in VAC may be the demonstration that
dopamine receptors of the 1, 2, 4 and 5 subtype are
expressed in follicular granulosa and in luteal cells
which opens the possibility that the dopaminergic
compounds in VAC promote follicular development
and luteal function [26–28].
The issue of a relation between premenstrual symp-
toms, particularly of premenstrual mastodynia and the
effectiveness of VAC preparations was recently reviewed
by van Die et al. [8]. This review lacks, however, a num-
ber of European, particularly East European studies. A
wider review of placebo controlled studies utilizing VAC
extract are shown in Table 2a-c. In all, but one of a total
of 21 well conducted, placebo- or comparator controlled
clinical trials such effects were well documented.
Results of studies not included in the recent review by
van Die [8] are briefly discussed in the following:
Women who start contraception with combined oral
contraceptives (COC) frequently experience mastodynia
which may last several months. Of particular interest is
therefore the large study involving patients who suffer
from mastodynia under COC [29]. In this study BNO
1095 (Mastodynon) proved highly effective to reduce the
COC induced painful sensations.
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In a solid comparator controlled trial the effects of
a treatment with 40 mg of a dried VAC fruit prepar-
ation for 3 months on premenstrual mastalgia, other
PMS symptoms an on latent hyperprolactinemia in
2×24 patients were compared with effects of
2×2.5 mg bromocriptine [30]. Although bromocriptine
was more effective to reduce serum prolactin levels
into the normal range, the VAC preparation reduced
mastalgia and PMS symptoms more efficiently than
the synthetic dopamine agonist. While a small num-
ber of VAC treated women reported mild side effects
(8.3% experienced headache and 5.8% nausea), such
effects occurred more frequently in the bromocriptine
treated women (21% headache, 15.8% nausea and
12.3% constipation).
In a large study, comprising 129 women, the effects of
40 mg dried VAC fruit on latent hyperprolactinemia in
patients suffering from mastodynia were compared to
those of a treatment with bromocriptine or Dostinex.
The latent hyperprolactinemia was successfully treated,
i.e. prolactin levels were normalized in all 3 treatment
groups which caused cessation of the painful breast sen-
sations. Interestingly mammary duct thickness was
reduced by the 2 synthetic but not by the VAC
preparation.
In another trial severity of PMS and of premenstrual
mastodynia was evaluated in 31 subjects with latent
hyperprolactinemia prior to and after treatment with
40 mg of a VAC dried fruit preparation, which resulted
in a significant reduction of both parameters [31].
In summary for the efficacy of VAC preparations and
premenstrual PMS and mastodynia: Almost all placebo
controlled studies published hitherto agree that extracts
of the fruit of this plant have beneficial effects on PMS,
particularly on premenstrual mastodynia (Table 2).
Fibrocystic mastopathy (FCM)
Fibrocystic mastopathy is the most common mam-
mary pathology and affects 60–80% of women in the
reproductive age [32–34]. Many women are frightened
that the development of fibrous nodes and/or cysts
indicates malignity and there is evidence that the in-
cidence of mammary cancers is indeed higher in
women with fibrocystic mastopathy [35]. These fibro-
cystic phenomena increase mammographic breast
density which represents a risk for the development
of mammary carcinomas (for review s.36). The eti-
ology of FCM is not totally clear: Estrogens and pro-
gestins in combination with latent hyperprolactinemia
are the most commonly accused hormones which
cause proliferation of mammary gland epithelia and
connective tissue and which results in enlargement of
ducts into cysts and proliferated connective tissue
cause the nods [32]. There is also evidence that pa-
tients with high mammographic density have elevated
prolactin levels [36] On the other hand many patients
with FCM have normal prolactin levels. A possible
explanation for this phenomenon is a mutation of
prolactin receptors which results in their hypersensi-
tivity [37]. There is also some recently described evi-
dence that such mutated prolactin receptors may be
constitutively active [38]. Under these conditions a
number of paracrine acting factors are locally secreted
which stimulate further proliferation of surrounding
cells [39]. These abnormalities seem often to be ac-
companied increased local by production of proin-
flammatory cytokines and/or higher susceptibility of
cytokine receptors due to gene polymorphisms [39]
causing local, often painful inflammatory processes
and consequently high local oxidative stress. In each
case, it appears from early studies that dopaminergic
drugs are able to reduce both subjectively felt pain
and objectively measured fibrocystic structures. The
most detailed and recent information of effects of
VAC preparations on FCM with or without latent
hyperprolactinemia or mastodynia stem from East
European studies. A brief overview of these studies is
given in Table 2 and further detailed in the following
text.
Two studies addressed alternatives to the disturbed
estradiol/progesterone relation as causative factor for
Fig. 8 In one of the studies shown in Fig. 7 (Wuttke et al. 2003)
treatment of PMDY patients with the VAC 1095 containing
preparations resulted in significantly lower midluteal serum
prolactin levels. Such effects were not seen in the placebo
treated patients
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FCM. In one trial 90 women with FCM had signifi-
cantly higher serum prolactin levels in comparison to
20 women without mammary gland symptoms [40].
In this study differences in E2 metabolites in women
with primarily glandular or cystic or fibrotic compo-
nents were found. Similarly, in another study 60 pa-
tients with FCM were either treated with Mastodynon
or received a placebo preparation [41]. In 30 of the
patients the VAC preparation BNO 1095 normalized
the 16-α-hydroxy metabolites and increased the 2-α-
hydroxyderivatives of E2. Such effects were not seen
in the placebo group and. The authors claim that this
disturbance of E2 metabolism is the major reason for
the development of FCM.
In aother study 120 women with latent hyperprolac-
tinemia and mastalgia-some with nipple discharge,
some without-were either treated with 2.5 mg bromo-
criptine or 0.24 mg Dostinex or with 40 mg of a
dried VAC fruit preparation used to produce the VAC
extract BNO 1095. Pain was improved and serum
prolactin levels reduced in all groups. Severe side ef-
fects such as nausea and orthostatic dysregulation oc-
curred only in the bromocriptine group. The size of
mammary gland ducts, as measured by ultrasound
sonography became thinner in the bomocriptine and
the Dostinex group but not in the VAC group. Authors
conclude that AC BNO 1055 should be the treatment of
first choice in patients with mastodynia whereas Dostinex
should be given in more severe forms of FCM. Elevated
serum prolactin levels were also published for a group of
women suffering from FCM in combination with premen-
strual mastodynia [40].
It is also of interest that blockade of prolactin release by
bromocriptine prevented stimulation of lobulo-alveolar
tissue in women with FCM. This observation confirms
and extends earlier reports which demonstrated also a
higher prolactin release in women with fibrocystic masto-
pathy in response to a TRH stimulus [3].
Women with a latent or manifest hypothyroidism suf-
fer often from mastodynia [41–43] and are often hyper-
prolactinemic [44], a phenomenon which is easily
explainable: In an attempt to stimulate the thyroid func-
tion the hypothalamus releases high amounts of thyroid
hormone releasing hormone (TRH) which is also stimu-
latory to prolactin release.
Relation to breast cancer
A mammary cancer promoting effects of prolactin was
already suggested more than 50 years ago but it was for
a long time almost a dogma that this effect occurs only
in rodents. Indeed in rats high prolactin levels stimulate
mammary cancers. It is however, now well established
that in women local production of prolactin occurs in
the mammary gland and prolactin receptor mRNA and
its protein has also been demonstrated in mammary
gland tissue and is overexpressed in malignant breast
epithelia. Both, prolactin mRNA and the protein appear
to be overexpressed and to exert paracrine effects which
may be causally linked to development end growth of
mammary cancers. In addition high circulating prolactin
levels are present in most mammary cancer patients and
are indicators for progression of the tumor. Such high
prolactin levels in 2250 mammary cancer patients were
recently confirmed.
Taken together it appears now well established that
prolactin is indeed involved in generation and promo-
tion of breast cancer. This makes it highly likely that
such cancers may be prevented and their progression
slowed down by dopamine agonists. Particularly VAC
extracts with their low side effects seem favorable for
the prevention of breast cancer by reducing mastodynia
and fibrocystic mastopathy.
Conclusion
Despite small sample and often poorly defined patient
populations sizes in most studies, randomised, con-
trolled trials support the efficacy and tolerability of Vitex
agnus-castus extracts in the treatment of premenstrual
syndrome, premenstrual dysphoric disorder, premen-
strual mastodynia and mastalgia accompanied by latent
hyperprolactinaemia and of fibrocystic mastopathy. Fu-
ture investigations with Vitex agnus castus extracts
would benefit from use of tightly defined patient popula-
tions and common endpoints.
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